Skip to main content
Terug
XERS logo

Xeris Biopharma Holdings, Inc.

Datakwaliteit: 100%
XERS
NASDAQ Healthcare Biotechnology
€ 5,29
▼ € 0,32 (-5,70%)
Marktkapitalisatie: 912,16M
Dagbereik
€ 5,25 € 5,54
52-Weeksbereik
€ 3,81 € 10,08
Volume
1.873.971
50D / 200D Gem.
€ 6,75 / € 6,88
Vorige Slotkoers
€ 5,61

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 1646,5 0,3
P/B 66,6 2,9
ROE % 3,7
Net Margin % 0,2 3,8
Rev Growth 5Y % 55,8 10,0
D/E 2,8 0,2

Koersdoel Analisten

Hold
€ 13,50 +155.2%
Low: € 9,00 High: € 18,00
Forward K/W
46,8
Forward WPA
€ 0,12
WPA Groei (sch.)
+0,0%
Omzet Sch.
380 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,09
€ 1,06 – € 1,14
700 M 1
FY2029 € 0,89
€ 0,87 – € 0,93
610 M 1
FY2028 € 0,59
€ 0,38 – € 0,82
540 M 5

Belangrijkste Punten

Revenue grew 55,75% annually over 5 years — strong growth
Debt/Equity of 2,76 — high leverage
Generating 27,93M in free cash flow
P/E of 1646,50 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 12,03%
Cash machine — converts 5041,52% of earnings into free cash flow

Groei

Revenue Growth (5Y)
55,75%
Revenue (1Y)43,72%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC36,29%
Net Margin0,19%
Op. Margin8,53%

Veiligheid

Debt / Equity
2,76
Current Ratio2,19
Interest Coverage0,86

Waardering

P/E Ratio
1646,50
P/B Ratio66,63
EV/EBITDA33,70
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 43,72% Revenue Growth (3Y) 33,43%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 55,75% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 291,85M Net Income (TTM) 554.000,0
ROE N/A ROA 0,14%
Gross Margin 81,70% Operating Margin 8,53%
Net Margin 0,19% Free Cash Flow (TTM) 27,93M
ROIC 36,29% FCF Growth (3Y) N/A
Safety
Debt / Equity 2,76 Current Ratio 2,19
Interest Coverage 0,86 Dividend Yield 0,00%
Valuation
P/E Ratio 1646,50 P/B Ratio 66,63
P/S Ratio 3,13 PEG Ratio -22,52
EV/EBITDA 33,70 Dividend Yield 0,00%
Market Cap 912,16M Enterprise Value 838,88M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 291,85M 203,07M 163,91M 110,25M 49,59M
Net Income 554.000,0 -54,84M -62,26M -94,66M -122,73M
EPS (Diluted) 0,00 -0,37 -0,45 -0,70 -1,55
Gross Profit 238,43M 166,24M 135,27M 87,61M 36,27M
Operating Income 24,90M -33,65M -44,01M -81,94M -115,16M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 383,53M 323,06M 322,60M 344,52M 304,36M
Total Liabilities 369,84M 352,68M 329,38M 299,34M 209,13M
Shareholders' Equity 13,69M -29,62M -6,78M 45,19M 95,23M
Total Debt 37,76M 271,45M 229,19M 198,06M 88,07M
Cash & Equivalents 111,04M 71,62M 67,45M 121,97M 67,27M
Current Assets 240,31M 167,66M 156,26M 186,82M 142,60M
Current Liabilities 109,57M 100,44M 95,19M 73,62M 79,04M